Nascent Biotech, Inc. Announces 2 Additions to Scientific Advisory Board
San Diego, CA June 17, 2014 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announces announced that it has added two internationally renowned cancer experts to its scientific advisory board:
Dr. Santosh Kesari is the director of the Neuro-Oncology Program, director of the Neurotoxicity Treatment Center, director of the Translational Neuro-Oncology Laboratories at Moores Cancer Center and a Professor of Neurosciences at the University Of California San Diego School Of Medicine. Dr. Kesari will be the Principal Clinical Investigator in charge of the Phase I/II human clinical trials in brain cancer for its lead therapeutic monoclonal antibody product Pritumumab.
Dr. Eric F. Glassy is Board certified in Anatomic and Clinical Pathology with a specific interest in Hematopathology, Information Pathology and Digital Pathology as well as being the Medical Director at Pathology Inc. Dr. Glassy is a world recognized Pathologist who has served in several leadership positions in the College of American Pathologists and is a past board member of the CAP Foundation. Dr. Eric Glassy has also authored several publications in his fields of interest and has written and edited key textbooks in the field of pathology. Dr. Eric Glassy’s immunohistology work has confirmed and extended the specificity and comparability of the Pritumumab database.
Nascent Biotech’s Senior Management Team is honored to have Dr. Santosh Kesari and Dr. Eric Glassy as part of their Advisory board.
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Nascent Biotech, Inc.